Observation on Effect of Weifuchun Combined with Teprenone on Patients with Chronic Atrophic Gastritis and Intestinal Metaplasia

Objective The present study aimed to observe the effect of Weifuchun combined with teprenone on gastroscopy scores and serum inflammatory factors in patients with chronic atrophic gastritis (CAG) accompanied by intestinal metaplasia (IM). Methods The clinical data of 80 patients with CAG and IM diagnosed and treated in Jinhua Wenrong Hospital from January 2020 to January 2023 were selected. They were randomly divided into the observation group and the control group, with 40 patients in each group and all patients being treated for 3 months. The control group was treated with teprenone capsules, and the observation group was treated with Weifuchun tablets on the basis of the control group. Clinical efficacy, traditional Chinese medical symptom scores, gastroscopy scores and serum indicators in both groups were compared. Results After 3 months of treatment, the total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After 3 months of treatment, the scores of four traditional Chinese medical syndromes, including bloating/ stomachache, belching, dizziness, and loss of appetite, as well as gastroscopy scores, decreased in both groups. The levels of gastrin (GAS) and somatostatin (SOM) increased, while the levels of tumor necrosis factor alpha (TNF-α) and interleukin-8 (IL-8) decreased (two-sided P ＜ 0.05). After 3 months of treatment, the above indicators in the observation group were better than those in the control group (one-sided P ＜ 0.025). Conclusion This study confirms that the combined treatment of Weifuchun tablets and teprenone capsules can effectively improve clinical efficacy and pathological morphology of gastric mucosa in patients with CAG and IM, and alleviate inflammatory reactions.